Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Genetic Determinants of Clonal Hematopoiesis and Progression to Hematologic Malignancies in 479,117 Individuals

Jie Liu, Duc Tran, Irenaeus C.C. Chan, Brian Wiley, Caroline Watson, Armel L. Batchi-Bouyou, Xiaoyu Zong, Konrad H. Stopsack, Paul Pharoah, Li Ding, Jamie R Blundell, Yin Cao, Matthew J. Walter, Nilanjan Chatterjee, Kenneth Offit, Lucy Godley, Daniel C. Link, Zsofia Stadler, Kelly L. Bolton

Blood (2023) 142 (Supplement 1): 811.

https://doi.org/10.1182/blood-2023-182423

Published: 2023

Journal Articles

Venetoclax Combined with Daunorubicin and Cytarabine (2 + 6) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial

Blood (2023) 142 (Supplement 1): 969.

https://doi.org/10.1182/blood-2023-179205

Published: 2023

Journal Articles

Plasma Proteomic Signature Predicts Risk of Myeloid Neoplasm

J. Scott Beeler, Duc Tran, Jie Liu, Zilan Xin, Brian Wiley, Irenaeus C.C. Chan, Michael H. Kramer, Armel L. Batchi-Bouyou, Xiaoyu Zong, Matthew J. Walter, Sarantis Chlamydas, Francesca Ferraro, Stephen T. Oh, Ben Busby, Daniel C. Link, Yin Cao, Kelly L. Bolton

Blood (2023) 142 (Supplement 1): 940.

https://doi.org/10.1182/blood-2023-190857

Published: 2023

Journal Articles

Arcch: Improving the Performance of Clonal Hematopoiesis Variant Calling and Interpretation Using a Consensus Based Approach

Evelyn L Schmidt, Irenaeus C.C. Chan, Alex Panchot, Brian Wiley, Jie Liu, Lea Moukarzel, Yiwen Zhang, Daniel C. Link, Konrad Stopsack, Kelly L Bolton

Blood (2022) 140 (Supplement 1): 5762–5763.

https://doi.org/10.1182/blood-2022-170221

Published: 2022

Journal Articles

Dissecting the Knowns for the Unknowns: Refining the Classification of Genomic Variations in Hematological Diseases By the Clingen Hematological Cancer Taskforce (HCT)

Blood (2022) 140 (Supplement 1): 11810–11811.

https://doi.org/10.1182/blood-2022-170989

Published: 2022

Journal Articles

Preliminary Safety and Efficacy Results of EDI001: An Investigator Initiated Trial on CRISPR/Cas9-Modified Autologous CD34 + Hematopoietic Stem and Progenitor Cells for Patients with Transfusion Dependent β-Thalassemia

Blood (2022) 140 (Supplement 1): 10652–10653.

https://doi.org/10.1182/blood-2022-166365

Published: 2022

Journal Articles

Expert Curation of Somatic FLT3 Variants By the Clingen Somatic Hematologic Cancer Taskforce (ClinGen HCT)

Blood (2021) 138 (Supplement 1): 4387.

https://doi.org/10.1182/blood-2021-153546

Published: 2021

Journal Articles

Chimeric Antigen Receptor T Cell Therapy in the Relapsed or Refractory Multiple Myeloma with Extramedullary Disease--a Single Institution Observation in China

Baiyan Wang, MD PhD, Jie Liu, MD, Wan-Hong Zhao, MD PhD, Yin-Xia Chen, MD, Xing-Mei Cao, MD, Yun Yang, MD, Yi-Lin Zhang, MD, Fang-Xia Wang, MD PhD, Peng-Yu Zhang, MD PhD, Bo Lei, MD, Liu-Fang Gu, MD PhD, Jian-Li Wang, MD PhD, Frank Xiao-Hu Fan, MD PhD, Wang-Gang Zhang, MD PhD, Ai-Li He, MD PhD

Blood (2020) 136 (Supplement 1): 6.

https://doi.org/10.1182/blood-2020-140243

Published: 2020

Journal Articles

Shared Expression of CD93 and Other Antigens By AML and Endothelial Cells Highlights a Need for Rational Combinatorial Targeting

Rebecca M Richards, MDPhD, Feifei Zhao, Katherine A Murphy, Peng Xu, MD, Amy Fan, Elena Sotillo, PhD, Mads Daugaard, Htoo Zarni Oo, Jie Liu, Wan-Jen Hong, Poul Sorensen, Robbie G. Majzner, MD, Ravi Majeti, MD PhD, Crystal L. Mackall, MD

Blood (2020) 136 (Supplement 1): 22.

https://doi.org/10.1182/blood-2020-133988

Published: 2020

Journal Articles

3D Genomics of Acute Meyloid Leukemia Reveals the Imbalance between DNA Methylation Canyon Interactions and Leukemic Specific Enhancer Network Interactions

Xiaotian Zhang, PhD, Xue Qing David Wang, PhD, Haley Gore, MS, Pamela Himadewi, BSc, Fan Feng, Jie Liu, PhD

Blood (2020) 136 (Supplement 1): 45.

https://doi.org/10.1182/blood-2020-141708

Published: 2020

Journal Articles

Developing a Novel Anti-CD19/CD20 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Relapsed/Refractory (r/r) B-Cell NHL

Blood (2020) 136 (Supplement 1): 8.

https://doi.org/10.1182/blood-2020-137826

Published: 2020

Journal Articles

Early Clinical Results of a Novel Anti-CD20 Chimeric Antigen Receptor (CAR)-T Cell Therapy for B-Cell NHL Patients Who Are Relapsed/Resistant Following CD19 CAR-T Therapy

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-138538

Published: 2020

Journal Articles

Selectively and Efficiently Expanding Natural Killer Cells in Vitro

Xuzhang Lu, PhD, Jie Liu, Master, Jia Zhuxia, PhD, Xiaoqing Ouyang, Baoan Chen, MDPhD

Blood (2020) 136 (Supplement 1): 20.

https://doi.org/10.1182/blood-2020-141778

Published: 2020

Journal Articles

Expert Curation of Somatic Variants in Hematological Malignancies By the Clingen Somatic Hematological Cancer Taskforce (ClinGen HCT)

Blood (2020) 136 (Supplement 1): 23.

https://doi.org/10.1182/blood-2020-143028

Published: 2020

Journal Articles

Manufacturing Scale-up and Preclinical Development of ET-01, Autologous CD34 + Cells with the BCL11A Erythroid Enhancer Edited By CRISPR/Cas9, for Patients with β-Thalassemia Major

Riguo Fang, PhD, Pengfei Yuan, PhD, Lingling Yu, Bachelor, Huihui Yang, Master, Jie Liu, Master, Jia Shi, PhD, Yongjian Zhang, PhD, Wei Zhang, PhD, Yiding Zhao, PhD, Zhiyong Peng, MD, Chunfu Li, MD, Yun Li, MD, Dong Wei, PhD

Blood (2019) 134 (Supplement_1): 965.

https://doi.org/10.1182/blood-2019-126499

Published: 2019

Journal Articles

Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2019) 134 (Supplement_1): 579.

https://doi.org/10.1182/blood-2019-124953

Published: 2019

Journal Articles

An All Antibody Approach for Conditioning Bone Marrow for Hematopoietic Stem Cell Transplantation with Anti-cKIT and Anti-CD47 in Non-Human Primates

Kristopher D Marjon, PhD, James Y Chen, MD PhD, Jiaqi Duan, MS, Timothy S Choi, BS, Kavitha Sompalli, MS, Dongdong Feng, PhD, Ofelia Mata, Sharline Chen, B.S., Leslie Kean, MD PhD, Mwe Mwe Chao, MD, Mark Chao, MD PhD, Chris H Takimoto, MD PhD, Balaji Agoram, PhD, Cynthia E. Dunbar, MD, Ravi Majeti, MD PhD, Irving L Weissman, MD, Jie Liu, PhD MD, Jens-Peter Volkmer, MD

Blood (2019) 134 (Supplement_1): 4428.

https://doi.org/10.1182/blood-2019-131490

Published: 2019

Journal Articles

Efficacy and Adverse Reactions of Gemcitabine Combined with Cyclophosphamide, Vinblastine and Prednisone Hydrogenation Regiments in Relapse and/or Refractory Non-Hodgkin's Lymphoma

Baiyan Wang, MD PhD, Jie Liu, MD, Yin-Xia Chen, MD, Xing-Mei Cao, MD, Wan-Hong Zhao, MD PhD, Jian-Li Wang, MD PhD, Xiao-Rong Ma, MD PhD, Yun Yang, MD, Peng-Yu Zhang, MD PhD, Fang-Xia Wang, MD PhD, Liu-Fang Gu, MD PhD, Bo Lei, MD, Jin Wang, MD PhD, Ju Bai, PhD, Yi-Lin Zhang, MD, Yan Xu, Ai-Li He, MD PhD, Wang-Gang Zhang, MD PhD

Blood (2018) 132 (Supplement 1): 5393.

https://doi.org/10.1182/blood-2018-99-116600

Published: 2018

Journal Articles

RBC-Specific CD47 Pruning Confers Protection and Underlies the Transient Anemia in Patients Treated with Anti-CD47 Antibody 5F9

James Y Chen, MD PhD, Kelly Marie McKenna, BS, Timothy S Choi, BS, Jiaqi Duan, MS, Lynette Brown, MSc, Jennifer J Stewart, PhD, Kavitha Sompalli, MS, Paresh Vyas, Stanley Schrier, MD, Ravindra Majeti, MD PhD, Irving L Weissman, MD, Kyle Elrod, BS, Mark Ping Chao, MD PhD, Chris H Takimoto, MD PhD, Jie Liu, PhD MD, Jens-Peter Volkmer, MD

Blood (2018) 132 (Supplement 1): 2327.

https://doi.org/10.1182/blood-2018-99-115674

Published: 2018

Journal Articles

Updated Analysis of a Phase 1, Open-Label Study of LCAR-B38M, a Chimeric Antigen Receptor T Cell Therapy Directed Against B-Cell Maturation Antigen, in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2018) 132 (Supplement 1): 955.

https://doi.org/10.1182/blood-2018-99-110548

Published: 2018

NARROW

Genetic Determinants of Clonal Hematopoiesis and Progression to Hematologic Malignancies in 479,117 Individuals

Venetoclax Combined with Daunorubicin and Cytarabine (2 + 6) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial

Plasma Proteomic Signature Predicts Risk of Myeloid Neoplasm

Arcch: Improving the Performance of Clonal Hematopoiesis Variant Calling and Interpretation Using a Consensus Based Approach

Dissecting the Knowns for the Unknowns: Refining the Classification of Genomic Variations in Hematological Diseases By the Clingen Hematological Cancer Taskforce (HCT)

Preliminary Safety and Efficacy Results of EDI001: An Investigator Initiated Trial on CRISPR/Cas9-Modified Autologous CD34 + Hematopoietic Stem and Progenitor Cells for Patients with Transfusion Dependent β-Thalassemia

Expert Curation of Somatic FLT3 Variants By the Clingen Somatic Hematologic Cancer Taskforce (ClinGen HCT)

Chimeric Antigen Receptor T Cell Therapy in the Relapsed or Refractory Multiple Myeloma with Extramedullary Disease--a Single Institution Observation in China

Shared Expression of CD93 and Other Antigens By AML and Endothelial Cells Highlights a Need for Rational Combinatorial Targeting

3D Genomics of Acute Meyloid Leukemia Reveals the Imbalance between DNA Methylation Canyon Interactions and Leukemic Specific Enhancer Network Interactions

Developing a Novel Anti-CD19/CD20 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Relapsed/Refractory (r/r) B-Cell NHL

Early Clinical Results of a Novel Anti-CD20 Chimeric Antigen Receptor (CAR)-T Cell Therapy for B-Cell NHL Patients Who Are Relapsed/Resistant Following CD19 CAR-T Therapy

Selectively and Efficiently Expanding Natural Killer Cells in Vitro

Expert Curation of Somatic Variants in Hematological Malignancies By the Clingen Somatic Hematological Cancer Taskforce (ClinGen HCT)

Manufacturing Scale-up and Preclinical Development of ET-01, Autologous CD34 + Cells with the BCL11A Erythroid Enhancer Edited By CRISPR/Cas9, for Patients with β-Thalassemia Major

Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

An All Antibody Approach for Conditioning Bone Marrow for Hematopoietic Stem Cell Transplantation with Anti-cKIT and Anti-CD47 in Non-Human Primates

Efficacy and Adverse Reactions of Gemcitabine Combined with Cyclophosphamide, Vinblastine and Prednisone Hydrogenation Regiments in Relapse and/or Refractory Non-Hodgkin's Lymphoma

RBC-Specific CD47 Pruning Confers Protection and Underlies the Transient Anemia in Patients Treated with Anti-CD47 Antibody 5F9

Updated Analysis of a Phase 1, Open-Label Study of LCAR-B38M, a Chimeric Antigen Receptor T Cell Therapy Directed Against B-Cell Maturation Antigen, in Patients with Relapsed/Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only